BIOTRONIK Introduces a Complete CRT Solution with the Ilivia Series

Published
Wednesday, February 1, 2017

New Generation of CRT-Ds Offers Physicians More Choice to Optimize Cardiac Resynchronization Therapy with Energy-Efficient MultiPole Pacing, Award-Winning MRI AutoDetect and BIOTRONIK Home Monitoring

BERLIN, Germany, February 1, 2017 – BIOTRONIK has launched a new series of cardiac resynchronization therapy (CRT) devices with several functionalities that allow physicians to offer an all-inclusive and individualized solution for optimized CRT.

“BIOTRONIK’s new CRT-Ds are equipped with numerous features that address physicians’ concerns about cardiac resynchronization therapy,” commented Dr. Christof Kolb, German Heart Center, Munich, Germany. “The energy-efficient MultiPole Pacing has great potential to increase patients’ response to CRT and to sustain this in the long-term.”

BIOTRONIK’s Ilivia series of CRT-Ds is specifically designed to address the 30 to 40 percent non-response rate to CRT1 without causing disproportionate additional battery drain. The energy-efficient system features MultiPole Pacing (MPP) for sequential or simultaneous pacing in the left ventricle (LV) that is individually programmable for an increased response rate. To further improve therapy success, this is complemented by a diverse portfolio of LV leads for different patient anatomies and target veins, including a newly launched Sentus QP lead with alternative pole-spacing for short to medium veins.

Since CRT patients are likely to require an MRI scan during their healthcare journey, the Ilivia CRT-D offers ProMRI® and is equipped with BIOTRONIK’s award-winning MRI AutoDetect feature, which enables the device to automatically recognize an MRI environment within a programmable time window, and switch itself to and from MRI mode. This simplifies the process of MRI scans for both patients and physicians and decreases the duration of reduced therapy, offering increased patient safety. “The launch of our latest generation of CRT-Ds and LV leads marks a significant expansion of our CRT portfolio,” said Senior Vice President at BIOTRONIK Manuel Ortega. “With a complete and innovative CRT solution, we want to empower physicians to offer a superior solution for heart patients that covers the entire duration of therapy and post-implantation care.”

About the Ilivia Series

The Ilivia series marks BIOTRONIK’s newest generation of CRT-Ds and ICDs. For improved management of CRT response, the CRT-Ds take advantage of energy-efficient MultiPole Pacing technology for sequential or simultaneous pacing along the left ventricular lead. A further programmable option enables the use of BIOTRONIK’s unique DX technology in CRT, delivering atrial sensing in patients not receiving an atrial lead. Ilivia CRT-Ds offer ProMRI® and include the company’s award-winning MRI AutoDetect and BIOTRONIK Home Monitoring® solutions for long-term patient care.

About BIOTRONIK

A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring®; Pulsar, the world’s first 4 F compatible stent for treating long lesions; Orsiro, the industry’s first hybrid drug-eluting stent; and the world’s first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.

For more information, visit: https://www.biotronik.com
Twitter: Biotronik_News
LinkedIn: www.linkedin.com/company/biotronik